Boston Scientific has announced a definitive agreement to acquire Penumbra for $14.5 billion in an all-cash transaction, marking one of the largest deals in the medical device sector this year. The acquisition accelerates Boston Scientific’s expansion into stroke and neurovascular interventions.
- Boston Scientific agrees to acquire Penumbra for $14.5 billion in all-cash transaction
- Deal values Penumbra shares at $297 each, a 38% premium to pre-announcement trading levels
- Expected closing date: Q2 2026, pending regulatory approvals
- Combined neurovascular revenue projected at $3.2 billion annually by 2028
- Penumbra’s key products include EmboTrap and Indigo aspiration systems
- Acquisition strengthens Boston Scientific’s competitive edge in stroke intervention market
Boston Scientific Corp. has entered into a definitive agreement to acquire Penumbra, Inc., a leading developer of endovascular solutions for stroke and neurovascular disorders, in a cash transaction valued at $14.5 billion. The deal, expected to close in the second quarter of 2026, underscores Boston Scientific’s strategic pivot toward high-growth specialty markets within interventional medicine. Penumbra’s portfolio includes FDA-approved devices such as the EmboTrap and Indigo aspiration systems, which are widely used in acute ischemic stroke treatment. The $14.5 billion price tag reflects a significant premium over Penumbra’s recent trading value and signals strong confidence in the long-term demand for advanced neurovascular therapies. Post-acquisition, Boston Scientific expects to integrate Penumbra’s R&D pipeline with its own innovation engine, aiming to accelerate development timelines and expand commercial reach across North America, Europe, and Asia-Pacific markets. The combined entity is projected to generate approximately $3.2 billion in annual revenue from neurovascular products by 2028. Market analysts note that the acquisition strengthens Boston Scientific’s position against competitors like Medtronic and Stryker, particularly in the rapidly growing stroke intervention segment. Investors have reacted positively, with Boston Scientific’s stock rising 4.2% in after-hours trading following the announcement. Penumbra shareholders will receive $297 per share, representing a 38% premium to the 30-day volume-weighted average price prior to the deal's disclosure. The transaction is subject to customary regulatory approvals, including clearance from the U.S. Department of Justice and European Commission. Integration plans are underway, with leadership transitions expected to begin in March 2026, ensuring minimal disruption to current operations and clinical supply chains.